Nieuw-Zeeland - Engels - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - hydromorphone hydrochloride 16mg (+ 9% overage to account for residual drug retained in capsule shell) - modified release tablet - 16 mg - active: hydromorphone hydrochloride 16mg (+ 9% overage to account for residual drug retained in capsule shell) excipient: butylated hydroxytoluene cellulose acetate hypromellose iron oxide black macrogol 3350 magnesium stearate opacode black ns-78-17821 opadry clear ys-1-19025-a opadry yellow y-30-12863-a polyethylene oxide povidone sodium chloride - jurnista is indicated in the treatment of moderate to severe chronic pain.

Nieuw-Zeeland - Engels - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - hydromorphone hydrochloride 8mg (+ 9% overage to account for residual drug retained in capsule shell) - modified release tablet - 8 mg - active: hydromorphone hydrochloride 8mg (+ 9% overage to account for residual drug retained in capsule shell) excipient: butylated hydroxytoluene cellulose acetate hypromellose iron oxide black macrogol 3350 magnesium stearate opacode black ns-78-17821 opadry clear ys-1-19025-a opadry red y-30-15595-a polyethylene oxide povidone sodium chloride - jurnista is indicated in the treatment of moderate to severe chronic pain.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - retapamulin -

Australië - Engels - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - rivastigmine, quantity: 27 mg - drug delivery system, transdermal - excipient ingredients: acrylates copolymer; dl-alpha-tocopherol; dimeticone 12500; ethyl acetate; methylated trimethylated silica; acrylic acid; 2-ethylhexyl acrylate; methyl acrylate; glycidyl methacrylate; 2,2'-azobisisobutyronitrile; hexane - exelon / prometax is indicated for the treatment of patients with mild, moderate and severe dementia of the alzheimer's type.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - rivastigmine, quantity: 18 mg - drug delivery system, transdermal - excipient ingredients: dimeticone 12500; acrylates copolymer; dl-alpha-tocopherol; ethyl acetate; acrylic acid; 2-ethylhexyl acrylate; methyl acrylate; glycidyl methacrylate; 2,2'-azobisisobutyronitrile; hexane; methylated trimethylated silica - exelon / prometax is indicated for the treatment of patients with mild, moderate and severe dementia of the alzheimer's type.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - rivastigmine, quantity: 9 mg - drug delivery system, transdermal - excipient ingredients: acrylates copolymer; dimeticone 12500; dl-alpha-tocopherol; ethyl acetate; acrylic acid; 2-ethylhexyl acrylate; methyl acrylate; glycidyl methacrylate; 2,2'-azobisisobutyronitrile; hexane; methylated trimethylated silica - exelon / prometax is indicated for the treatment of patients with mild, moderate and severe dementia of the alzheimer's type.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

aurobindo pharma australia pty ltd - duloxetine hydrochloride -

Australië - Engels - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - duloxetine hydrochloride, quantity: 33.66 mg (equivalent: duloxetine, qty 30 mg) - capsule, enteric - excipient ingredients: purified talc; crospovidone; titanium dioxide; hypromellose; triethyl citrate; hyprolose; hypromellose phthalate; maize starch; sucrose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; indigo carmine; gelatin; sodium lauryl sulfate - duloxetine is indicated for the treatment of major depressive disorder (mdd).,duloxetine is indicated for the treatment of generalised anxiety disorder (gad).

Australië - Engels - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - duloxetine hydrochloride, quantity: 67.32 mg (equivalent: duloxetine, qty 60 mg) - capsule, enteric - excipient ingredients: crospovidone; titanium dioxide; hyprolose; hypromellose phthalate; triethyl citrate; hypromellose; purified talc; maize starch; sucrose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; indigo carmine; iron oxide yellow; gelatin; sodium lauryl sulfate - duloxetine is indicated for the treatment of major depressive disorder (mdd).,duloxetine is indicated for the treatment of generalised anxiety disorder (gad).

Australië - Engels - Department of Health (Therapeutic Goods Administration)

aurobindo pharma australia pty ltd - duloxetine hydrochloride -